Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Pharmacology and pharmacogenetics of pediatric ADHD with associated aggression: a review.

Patel BD, Barzman DH.

Psychiatr Q. 2013 Dec;84(4):407-15. doi: 10.1007/s11126-013-9253-7. Review.

PMID:
23443759
2.

Mechanism of action of agents used in attention-deficit/hyperactivity disorder.

Wilens TE.

J Clin Psychiatry. 2006;67 Suppl 8:32-8. Review.

3.

Dopamine transporter genotype influences the physiological response to medication in ADHD.

Gilbert DL, Wang Z, Sallee FR, Ridel KR, Merhar S, Zhang J, Lipps TD, White C, Badreldin N, Wassermann EM.

Brain. 2006 Aug;129(Pt 8):2038-46. Epub 2006 Jun 7.

4.

Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.

Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH.

Arch Gen Psychiatry. 2012 Sep;69(9):952-61. doi: 10.1001/archgenpsychiatry.2011.2053.

PMID:
22945622
5.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
6.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
7.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
8.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Gibson AP, Bettinger TL, Patel NC, Crismon ML.

Ann Pharmacother. 2006 Jun;40(6):1134-42. Epub 2006 May 30. Review.

PMID:
16735655
10.

Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.

Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF.

J Am Acad Child Adolesc Psychiatry. 2009 Sep;48(9):884-93. doi: 10.1097/CHI.0b013e3181b26e9f.

11.

Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.

Huang YS, Tsai MH.

CNS Drugs. 2011 Jul;25(7):539-54. doi: 10.2165/11589380-000000000-00000. Review. Erratum in: CNS Drugs. 2011 Nov 1;25(11):932. Dosage error in article text.

PMID:
21699268
12.

Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.

Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.

Appl Health Econ Health Policy. 2012 Nov 1;10(6):381-95. doi: 10.2165/11641870-000000000-00000. Erratum in: Appl Health Econ Health Policy. 2013 Jun;11(3):309. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
23113551
13.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
14.

Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.

Isaksson J, Hogmark Å, Nilsson KW, Lindblad F.

Psychiatry Res. 2013 Oct 30;209(3):740-1. doi: 10.1016/j.psychres.2013.06.011. Epub 2013 Jul 11.

PMID:
23850434
15.
16.

[Autism and attention deficit hyperactivity disorder: pharmacological intervention].

Fernández-Jaén A, Martín Fernández-Mayoralas D, Fernández-Perrone AL, Calleja-Pérez B, Muñoz-Jareño N, López-Arribas S.

Rev Neurol. 2013 Sep 6;57 Suppl 1:S205-10. Review. Spanish.

17.

Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.

Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.

Expert Rev Neurother. 2011 Apr;11(4):499-508. doi: 10.1586/ern.11.18.

PMID:
21469923
18.

Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.

Biederman J, Spencer T, Wilens T.

Int J Neuropsychopharmacol. 2004 Mar;7(1):77-97. Epub 2004 Jan 21. Review.

PMID:
14733627
19.

Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders.

Pringsheim T, Steeves T.

Cochrane Database Syst Rev. 2011 Apr 13;(4):CD007990. doi: 10.1002/14651858.CD007990.pub2. Review.

PMID:
21491404
20.

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.

Santosh PJ, Sattar S, Canagaratnam M.

CNS Drugs. 2011 Sep 1;25(9):737-63. doi: 10.2165/11593070-000000000-00000. Review.

PMID:
21870887
Items per page

Supplemental Content

Write to the Help Desk